Confo Therapeutics

Foundation date

11/06/2015

Sector

#Biotechnology - Therapeutics

Subsector

Confo Therapeutics’ unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible GPCRs as drug targets.

This technology platform combined with the pharmacologic and biologic insight it provides, allows Confo to build a multi-indication pipeline of drug candidates with the potential to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying treatments.

Confo Therapeutics was spun out of Vrije Universiteit Brussel (VUB) and VIB in 2015. Supported by international life-science focused investors and led by an experienced team of entrepreneurial professionals and scientists from successful biopharmaceutical companies, Confo Therapeutics benefits from the rich scientific and innovative ecosystem in Belgium.

Latest news

  • Antonin (Tony) de Fougerolles appointed as new Chair of etherna

    Tuesday July 16th 2024

  • ONTOFORCE Achieves ISO 27001:2022 Certification: A Milestone in Information Security and Trust

    Tuesday July 16th 2024

  • Ghent University spin-off Trince wins Nature Spinoff Prize

    Monday July 15th 2024